Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports ...
Zacks Research decreased their Q1 2025 EPS estimates for shares of Pfizer in a report issued on Thursday, January 2nd. Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback